Firstly, they do not clearly distinguish between surrogate end points for benefits and harms. As they suggest, harms rather than surrogates should be studied in trials. Although multiple end points should be studied when surrogates are used to assess long term benefits, actual benefits often cannot be studied, particularly in diseases such as epilepsy when the final end points are intermittent; and in population studies of diseases such as hypertension that require long term treatment to prevent final end points. They cite Law et al as showing that antihypertensive drugs may not reduce the long term risk of stroke.
2 However, Law et al, reported that "all the classes of blood pressure lowering drugs have a similar effect in reducing CHD events and stroke for a given reduction in blood pressure;" blood pressure is an excellent surrogate for the long term benefits of treating hypertension.
Secondly, their taxonomy of types of surrogate is incomplete. Elsewhere I have described five different types of surrogates, and there are probably more. Thirdly, their use of the term hard to refer to clinically relevant end points is misleading. The terms hard and soft in relation to types of data have not been widely discussed, but a definitive description was given by Feinstein some 30 years ago. 4 Briefly, hard data are acquired objectively, not subjectively; are preservable (an x ray film can be reassessed and a blood measurement repeated); and are measured on a dimensional rather than an ordinal or a nominal scale. Many surrogates are hard end points by this definition. It would be better to contrast surrogate end points with clinically relevant end points.
